Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19
Kalil AC, et al.〔N Engl J Med. 2021 Mar 4;384(9):795-807〕（査読済み）
JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis
Walz L, et al.〔BMC Infect Dis. 2021 Jan 11;21(1):47〕（査読済み）
Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia
Abizanda P, et al.〔J Am Geriatr Soc. 2021 Oct;69(10):2752-2758〕（査読済み）
Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19
Izumo T, et al.〔Respir Investig. 2021 Aug 10:S2212-5345(21)00125-8〕（査読済み）
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
Marconi VC, et al.〔Lancet Respir Med. 2021 Aug 31:S2213-2600(21)00331-3〕（査読済み）
Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future (Review)